Literature DB >> 20229262

The Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) and their correlation with main symptoms experienced by patients with spondyloarthritis.

Euthalia Roussou1, Shahzabeen Sultana.   

Abstract

With the aim of assessing whether the Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) are reliable measures of disease activity and function in patients with spondyloarthritides (SpAs), 341 patients with SpA (representing ankylosing spondylitis (14.5%), psoriatic arthritis (27.3%), enteropathic arthritis (6.3%), reactive arthritis (4.9%), and undifferentiated arthritis (46.5%) were asked to complete the BASDAI and BASFI. They were asked to report what their main problems associated with the disease were from a list of seven symptoms: fatigue, neck pain, upper back pain, lower back pain, stiffness, joint pain or swelling, and pain with pressure on joints. Correlations between the main symptoms experienced by patients with SpAs and the indices, defined by Spearman's correlation coefficient, showed that BASDAI best correlated with neck pain [BASDAI 2 and total BASDAI score correlate strongly (p = 0.003 and 0.001, respectively), and BASDAI 1, 4, and 5 correlate moderately (p = 0.03, 0.02, and 0.01, respectively)], followed by stiffness, upper back pain, pain with pressure, lower back pain, fatigue, and joint pain. Stiffness correlated strongly with nine of ten items on BASFI (BASFI 1 showed moderate correlation, p = 0.01), followed by upper back pain (four of ten items correlated strongly, three of ten correlated moderately), neck pain (three of ten tasks correlated strongly and four of ten correlated moderately), lower back pain (one task correlated strongly, five moderately), joint pain and swelling (four tasks correlated moderately), fatigue (three tasks correlated moderately), and pain with pressure (two tasks correlated moderately). BASDAI and BASFI only partly reflect disease activity and patients' functional capacity in SpAs. An alternate instrument is required to assess SpA disease activity and functional capacity more precisely.

Entities:  

Mesh:

Year:  2010        PMID: 20229262     DOI: 10.1007/s10067-010-1411-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up.

Authors:  G Huerta-Sil; J C Casasola-Vargas; J D Londoño; R Rivas-Ruíz; J Chávez; C Pacheco-Tena; M H Cardiel; G Vargas-Alarcón; R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.

Authors:  A Spoorenberg; A van Tubergen; R Landewé; M Dougados; S van der Linden; H Mielants; H van de Tempel; D van der Heijde
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580

3.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

4.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

5.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

6.  Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

Authors:  Jan Brandt; Andre Khariouzov; Joachim Listing; Hildrun Haibel; Helmut Sörensen; Martin Rudwaleit; Joachim Sieper; Jurgen Braun
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

7.  Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?

Authors:  William J Taylor; Andrew A Harrison
Journal:  Arthritis Rheum       Date:  2004-06-15

8.  ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

Authors:  D van der Heijde; E Lie; T K Kvien; J Sieper; F Van den Bosch; J Listing; J Braun; R Landewé
Journal:  Ann Rheum Dis       Date:  2008-12-05       Impact factor: 19.103

  8 in total
  4 in total

1.  Phenotypic and clinical differences between Caucasian and South Asian patients with psoriatic arthritis living in North East London.

Authors:  Euthalia Roussou; Sunil Chopra; Danny Lunda Ngandu
Journal:  Clin Rheumatol       Date:  2012-12-18       Impact factor: 2.980

2.  Normative values for the Bath Ankylosing Spondylitis Functional Index in the general population compared with ankylosing spondylitis patients in Morocco.

Authors:  Ghizlane Wariaghli; Fadoua Allali; Kenza Berrada; Zineb Idrissi; Ihsane Hmamouchi; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2012-03-21       Impact factor: 2.362

3.  Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey.

Authors:  S Rifbjerg-Madsen; A W Christensen; R Christensen; M L Hetland; H Bliddal; L E Kristensen; B Danneskiold-Samsøe; K Amris
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

4.  Analysis of HLA-B15 and HLA-B27 in spondyloarthritis with peripheral and axial clinical patterns.

Authors:  John Londono; Ana Maria Santos; Paola Peña; Enrique Calvo; Luis R Espinosa; John D Reveille; Gilberto Vargas-Alarcon; Carlos A Jaramillo; Rafael Valle-Oñate; Mabel Avila; Consuelo Romero; Juan F Medina
Journal:  BMJ Open       Date:  2015-11-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.